Literature DB >> 25038736

Targeting apoptosis in autoimmune hepatitis.

Albert J Czaja1.   

Abstract

Apoptosis is the predominant mechanism of liver cell death in autoimmune hepatitis, and interventions that can modulate this activity are emerging. The aim of this review was to describe the apoptotic mechanisms, possible aberrations, and opportunities for intervention in autoimmune hepatitis. Studies cited in PubMed from 1972 to 2014 for autoimmune hepatitis, apoptosis in liver disease, apoptosis mechanisms, and apoptosis treatment were examined. Apoptosis is overactive in autoimmune hepatitis, and the principal pathway of cell death is receptor mediated. Surface death receptors are activated by extrinsic factors including liver-infiltrating cytotoxic T cells and the cytokine milieu. The executioner caspases 3 and 7 cleave nuclear deoxyribonucleic acid, and the release of apoptotic bodies can stimulate inflammatory, immune, and fibrotic responses. Changes in mitochondrial membrane permeability can be initiated by caspase 8, and an intrinsic pathway of apoptosis can complement the extrinsic pathway. Defects in the apoptosis of activated effector cells can prolong their survival and sustain the immune response. Caspase inhibitors have been used in diverse experimental and human diseases to retard apoptosis. Oligonucleotides that inhibit the signaling of toll-like receptors can limit the presentation of auto-antigens, and inhibitors of apoptosis that extend the survival of effector cells can be blocked by antisense oligonucleotides. Mechanisms that enhance the clearance of apoptotic bodies and affect key signaling pathways are also feasible. Interventions that influence the survival of liver and effector cells by altering their apoptosis are candidates for study in autoimmune hepatitis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25038736     DOI: 10.1007/s10620-014-3284-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  139 in total

1.  Soluble intracellular adhesion molecule, M30 and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases.

Authors:  Gerald Denk; Ahmed-Jawid Omary; Florian Paul Reiter; Simon Hohenester; Ralf Wimmer; Stefan Holdenrieder; Christian Rust
Journal:  Hepatol Res       Date:  2014-02-28       Impact factor: 4.288

2.  A novel isoform of TUCAN is overexpressed in human cancer tissues and suppresses both caspase-8- and caspase-9-mediated apoptosis.

Authors:  Masaaki Yamamoto; Toshihiko Torigoe; Kenjiro Kamiguchi; Yoshihiko Hirohashi; Katsuya Nakanishi; Chika Nabeta; Hiroko Asanuma; Tetsuhiro Tsuruma; Takashi Sato; Fumitake Hata; Tousei Ohmura; Koji Yamaguchi; Takehiro Kurotaki; Koichi Hirata; Noriyuki Sato
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

3.  Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases.

Authors:  S Jodo; S Kobayashi; N Kayagaki; N Ogura; Y Feng; Y Amasaki; A Fujisaku; M Azuma; H Yagita; K Okumura; T Koike
Journal:  Clin Exp Immunol       Date:  1997-01       Impact factor: 4.330

4.  Identification of a factor that links apoptotic cells to phagocytes.

Authors:  Rikinari Hanayama; Masato Tanaka; Keiko Miwa; Azusa Shinohara; Akihiro Iwamatsu; Shigekazu Nagata
Journal:  Nature       Date:  2002-05-09       Impact factor: 49.962

5.  Caspase-independent cell death and mitochondrial disruptions observed in the Apaf1-deficient cells.

Authors:  K Miyazaki; H Yoshida; M Sasaki; H Hara; G Kimura; T W Mak; K Nomoto
Journal:  J Biochem       Date:  2001-06       Impact factor: 3.387

6.  Disease activity in multiple sclerosis correlates with T lymphocyte expression of the inhibitor of apoptosis proteins.

Authors:  Y K Semra; O A Seidi; M K Sharief
Journal:  J Neuroimmunol       Date:  2002-01       Impact factor: 3.478

7.  Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis.

Authors:  Ali Canbay; Hajime Higuchi; Steven F Bronk; Makiko Taniai; Tom J Sebo; Gregory J Gores
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

8.  First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes.

Authors:  K L Valentino; M Gutierrez; R Sanchez; M J Winship; D A Shapiro
Journal:  Int J Clin Pharmacol Ther       Date:  2003-10       Impact factor: 1.366

9.  Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site.

Authors:  Haiying Sun; Zaneta Nikolovska-Coleska; Chao-Yie Yang; Liang Xu; York Tomita; Krzysztof Krajewski; Peter P Roller; Shaomeng Wang
Journal:  J Med Chem       Date:  2004-08-12       Impact factor: 7.446

10.  Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+ T-cells.

Authors:  J E Arends; A I M Hoepelman; N M Nanlohy; F J P Höppener; K R Hirsch; J G Park; D van Baarle
Journal:  Apoptosis       Date:  2011-09       Impact factor: 4.677

View more
  20 in total

Review 1.  Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors:  Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

Review 2.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 3.  Nature and Implications of Oxidative and Nitrosative Stresses in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-13       Impact factor: 3.199

Review 4.  Galectin-3 in autoimmunity and autoimmune diseases.

Authors:  Felipe L de Oliveira; Mariele Gatto; Nicola Bassi; Roberto Luisetto; Anna Ghirardello; Leonardo Punzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2015-07-03

5.  Role of ultrasound and microbubble-mediated heat shock protein 72 siRNA on ischemia-reperfusion liver injury in rat.

Authors:  Chungen Yan; Dongfang Zhu; Danwen Huang; Guoyuan Xia
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 6.  Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2018-04-18       Impact factor: 3.199

Review 7.  Cell mediators of autoimmune hepatitis and their therapeutic implications.

Authors:  Aldo J Montano-Loza; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

8.  Prevention of apoptosis averts glomerular tubular disconnection and podocyte loss in proteinuric kidney disease.

Authors:  Ievgeniia Burlaka; Linnéa M Nilsson; Lena Scott; Ulla Holtbäck; Ann-Christine Eklöf; Agnes B Fogo; Hjalmar Brismar; Anita Aperia
Journal:  Kidney Int       Date:  2016-05-21       Impact factor: 10.612

Review 9.  Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2021-04-09       Impact factor: 3.199

Review 10.  Incorporating mucosal-associated invariant T cells into the pathogenesis of chronic liver disease.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.